PolyPid Announces Presentation of Clinical Data at Surgical Infection Society 2022 Annual Meeting
Apr 23 - Apr 26, 2022
PETACH TIKVA, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the upcoming Surgical Infection Society (SIS) 2022 Annual Meeting, being held on April 23-26, 2022 in Dallas, TX.
The abstract, ‘Incisional microenvironments and reduction in SSIs in patients treated with a local doxycycline-eluting formulation,’ evaluates the addition of D-PLEX100 to the surgical site infection standard of care prophylaxis regimen in elective colorectal surgery. The presentation will include an oral review led by Dr. Anthony Senagore, Senior Medical Director of PolyPid, and will be available on https://www.polypid.com/ following the presentation.
